LDS/Medical Tests/Nordiazepam, Urine

Nordiazepam, Urine

Nordiazepam belongs to the class of drugs known as benzodiazepines. Nordiazepam is classified as a 1,4-benzodiazepine derivative and a major metabolite of diazepam, clorazepate, and prazepam. Although nordiazepam does exhibit similar pharmacologic effects as diazepam it is not as potent.

Nordiazepam is primarily used to treat anxiety and depression. It is also used as an adjunct for the treatment of skeletal muscle spasm and epileptic type seizures, and as a minor tranquilizer or sedative. Following an oral dose it is well absorbed with a bioavailability of about 100%.

Nordiazepam is the major metabolite of diazepam and results from metabolism by the cytochrome 450 system. Further metabolism of nordiazepam results in the formation of 3-hydroxy metabolites of diazepam, oxazepam, and temazepam. After a dose most of the nordiazepam is eliminated in the urine as the glucuronide conjugates of oxazepam, nordiazepam, and temazepam.

  • Drug abuse evaluation
  • Toxicity assessment
  • Patient Compliance
Any qualitative positive result from an immunoassay screening type test indicates only the presence of nordiazepam and does not necessarily correlate with the extent of physiological and psychological effects. Any positive result should be confirmed by a non-immunological method such as GC, LC/MS, or GC/MS.
Liquid Chromatography/Mass Spectroscopy (LC/MS) or Gas Chromatography/Mass Spectroscopy (GC/MS). The preferred method of detection is LC/MS. The main method of quantitation detection is via LC/MS or LC/MS/MS (liquid chromatography coupled with mass spectroscopy).

Fresh urine specimen collected in either a clean glass or plastic container. An acceptable urine specimen submitted for testing should be in the pH range of 3-11. Adulteration of the urine specimen can result in erroneous results.

Serum specimens that are collected in a non-gel red top tube are the preferred specimens of choice. Specimens should be spun and the serum separated and refrigerated.

Stability

  • Ambient: 3-5 days
  • Refrigeration: 5-7 days
  • Frozen: 30 days
Pharmacogenetic testing such as genotyping for *CYP3A4, CYP3A5, CYP2D6, CYP2C9, CYP2C19,* COMT and *OPRM1* variants could guide drug and dose selection. Supportive testing such as a liver profile, kidney profile, comprehensive metabolic panel, CBC, and testing for concomitant drugs may be appropriate.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • DEA Drug Fact Sheet
  • Levine B (ed). Principles of Forensic Toxicology, 4th Ed. Washington DC: AACC Press. Chapter 14, Benzodiazepines, pp. 237-251; 2013.
  • Baselt RC (ed). Analytical procedures for therapeutic drug monitoring and emergency toxicology, 2nd ed. Littleton, MA: PSG Publishing Co.; 1987.
  • Baselt RC (ed). Disposition of toxic drugs and chemicals in man, 6th ed. Foster City, CA: Biomedical Publications; 2002.
  • Fitzgerald R. Analytical toxicology of the benzodiazepines. AACC Therapeutic Drug Monitoring and Toxicology. 1995;16(7):169-79.
  • Harman JG, Limbird LE, Molinoff PB, Ruddon RW, Gilman AG (eds). Goodman and Gilman’s the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill Co.; 1996.
  • Wians FH. Benzodiazepine update. AACC Therapeutic Drug Monitoring and Toxicology. 1989;11(4):7-20.
  • Zherdev VP, Caccia S, Garattini S, Ekonomov AL. Species differences in phenazepam kinetics and metabolism. Euro J Drug Metab Pharm. 1982;7:191-6.